Join National Pharmaceutical Council Chief Science Officer Robert Dubois, Memorial Sloan Kettering Cancer Center’s Peter Bach, Institute for Clinical and Economic Review’s Sarah Emond, Northwestern University’s Craig Garthwaite and Tufts University’s Peter Neumann for a discussion of the tremendous value that will be created by a successful treatment for COVID-19. The panelists tackle several difficult questions such as:
- What role dose price play in the market?
- What elements of a therapy’s value should be evaluated?
- How should a drug’s benefits be divided between manufacturers and the public?
Watch the recap here.
(Source: National Pharmaceutical Council, August 14, 2020)